

W.J. "BILLY" TAUZIN, LOUISIANA
RALPH M. HALL, TEXAS
MICHAEL BILIRAKIS, FLORIDA
FRED UPTON, MICHIGAN
CLIFF STEARNS, FLORIDA
PAUL E. GILLMOR, OHIO
JAMES C. GREENWOOD, PENNSYLVANIA
CHRISTOPHER COX, CALIFORNIA
NATHAN DEAL, GEORGIA
RICHARD BURR, NORTH CAROLINA
ED WHITFIELD, KENTUCKY
CHARLIE NORWOOD, GEORGIA
BARBARA CUBIN, WYOMING
JOHN SHIMMUS, ILLINOIS
HEATHER WILSON, NEW MEXICO
JOHN B. SHADEGG, ARIZONA
CHARLES W. "CHIP" PICKERING, MISSISSIPPI
VITO FOSSELLA, NEW YORK
STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
CHARLES F. BASS, NEW HAMPSHIRE
JOSEPH R. PITTS, PENNSYLVANIA
MARY BONO, CALIFORNIA
GREG WALDEN, OREGON
LEE TERRY, NEBRASKA
MIKE FERGUSON, NEW JERSEY
MIKE ROGERS, MICHIGAN
DARRELL E. ISSA, CALIFORNIA
C.L. "BUTCH" OTTER, IDAHO
JOHN SULLIVAN, OKLAHOMA

ONE HUNDRED EIGHTH CONGRESS

U.S. House of Representatives
Committee on Energy and Commerce
Washington, DC 20515-6115

JOE BARTON, TEXAS
CHAIRMAN

December 3, 2004

JOHN D. DINGELL, MICHIGAN
HENRY A. WAXMAN, CALIFORNIA
EDWARD J. MARKEY, MASSACHUSETTS
RICK BOUCHER, VIRGINIA
EDOLPHUS TOWNS, NEW YORK
FRANK PALLONE, JR., NEW JERSEY
SHERROD BROWN, OHIO
BART GORDON, TENNESSEE
PETER DEUTSCH, FLORIDA
BOBBY L. RUSH, ILLINOIS
ANNA G. ESHOO, CALIFORNIA
BART STUPAK, MICHIGAN
ELIOT L. ENGEL, NEW YORK
ALBERT R. WYNN, MARYLAND
GENE GREEN, TEXAS
KAREN MCCARTHY, MISSOURI
TED STRICKLAND, OHIO
DIANA DEGETTE, COLORADO
LOIS CAPPS, CALIFORNIA
MICHAEL F. DOYLE, PENNSYLVANIA
CHRISTOPHER JOHN, LOUISIANA
TOM ALLEN, MAINE
JIM DAVIS, FLORIDA
JAN SCHAKOWSKY, ILLINOIS
HILDA L. SOLIS, CALIFORNIA
CHARLES A. GONZALEZ, TEXAS

BUD ALBRIGHT, STAFF DIRECTOR

Anthony S. Fauci, M.D.
Director, National Institute of
Allergy and Infectious Diseases
National Institutes of Health
6610 Rockledge Drive, MSC 6612
Bethesda, MD 20892-6612


Dear Dr. Fauci:

On November 18, 2004, you testified before the Subcommittee on Health and Subcommittee on Oversight and Investigations in a joint hearing entitled "Flu Vaccine: Protecting High-Risk Individuals and Strengthening the Market." We now request your response to several additional questions (attached).

Because we wish to include the questions and responses in the printed record of this hearing, please respond no later than Friday, December 17, 2004. Please fax and e-mail the responses. The faxed response should be directed to Eugenia Edwards, Committee on Energy and Commerce majority staff, at (202) 226-2447, and Voncille Hines, Committee on Energy and Commerce minority staff, at (202) 225-5288. The e-mail copy of the response should be in MS Word format and directed to Eugenia Edwards (Eugenia.Edwards@mail.house.gov) and Voncille Hines (Voncille.Hines@mail.house.gov). Due to the uncertainties of postal deliveries on Capitol Hill, your response should not be sent through the postal service.

If you have any questions, please contact John Ford, Minority Counsel with the Committee on Energy and Commerce, at (202) 226-3400.

Sincerely,



JOHN D. DINGELL
RANKING MEMBER

Attachment

Dr. Anthony S. Fauci
Page 2

cc: The Honorable Joe Barton, Chairman
Committee on Energy and Commerce

The Honorable Michael Bilirakis, Chairman
Subcommittee on Health

The Honorable Sherrod Brown, Ranking Member
Subcommittee on Health

The Honorable Greg Walden, Vice Chairman
Subcommittee on Oversight and Investigations

The Honorable Peter Deutch, Ranking Member
Subcommittee on Oversight and Investigations

Questions for Anthony S. Fauci, M.D.
Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
from the Honorable John D. Dingell
Committee on Energy and Commerce
regarding the November 18, 2004, Subcommittee on Health and
Subcommittee on Oversight and Investigations
Hearing entitled "Flu Vaccine: Protecting High-Risk Individuals and
Strengthening the Market"

1. Does the Administration have plans to submit legislation aimed at assuring an adequate and reliable supply of flu vaccines? If so, please describe the basic features of the legislation. If not, please explain.
2. Does the current structure of NIH provide you and your NIH colleagues with an optimal framework for conducting and supporting research on new vaccines in general, and flu vaccines in particular? If not, what changes do you recommend? Please specify which, if any, of these changes could be done administratively and which would require legislation.
3. One comment we heard at the hearing was that it is important for additional vaccine production capacity to be based in the United States and not somewhere else. According to this view, this is important for annual influenza vaccines, and especially important in the context of a pandemic. Do you agree? Please explain. If you agree, what policies do you think are needed to achieve that goal?
4. Can you please explain in detail how the Administration's \$100 million request for flu vaccine activities will be spent? Did you provide input into this request? If so, what amount did you recommend?